INTERVENTION 1:	Intervention	0
Bendamustine and Erlotinib	Intervention	1
bendamustine	CHEBI:135515	0-12
erlotinib	CHEBI:114785	17-26
Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.	Intervention	2
bendamustine	CHEBI:135515	64-76
erlotinib	CHEBI:114785	110-119
day	UO:0000033	80-83
day	UO:0000033	123-126
day	UO:0000033	146-149
Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.	Intervention	3
bendamustine	CHEBI:135515	65-77
erlotinib	CHEBI:114785	111-120
day	UO:0000033	81-84
day	UO:0000033	124-127
day	UO:0000033	147-150
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed breast cancer meeting 1 of the following criteria:	Eligibility	1
breast cancer	DOID:1612	25-38
Unresectable stage IIIB or IIIC disease	Eligibility	2
disease	DOID:4,OGMS:0000031	32-39
Stage IV disease	Eligibility	3
disease	DOID:4,OGMS:0000031	9-16
Must be negative for all of the following:	Eligibility	4
Estrogen receptor (< 10%)	Eligibility	5
estrogen	CHEBI:50114,BAO:0000760	0-8
receptor	BAO:0000281	9-17
Progesterone receptor (<10%)	Eligibility	6
progesterone	CHEBI:17026	0-12
receptor	BAO:0000281	13-21
HER-2 (negative FISH, IHC 0 - 1+, or IHC +2 with negative FISH)	Eligibility	7
Measurable or evaluable disease	Eligibility	8
disease	DOID:4,OGMS:0000031	24-31
No symptomatic or progressive CNS (central nervous system) metastases	Eligibility	9
progressive	HP:0003676	18-29
central nervous system	UBERON:0001017	35-57
Previously treated CNS metastases allowed provided all of the following criteria are met:	Eligibility	10
At least 8 weeks since prior radiation to brain or CNS metastases	Eligibility	11
brain	UBERON:0000955	42-47
No concurrent steroids	Eligibility	12
No leptomeningeal disease	Eligibility	13
disease	DOID:4,OGMS:0000031	18-25
PATIENT CHARACTERISTICS:	Eligibility	14
patient	HADO:0000008,OAE:0001817	0-7
Menopausal status not specified	Eligibility	15
ECOG (Eastern Cooperative Oncology Group) performance status 0-2	Eligibility	16
group	CHEBI:24433	35-40
Life expectancy  6 months	Eligibility	17
WBC > 1,500/mm³	Eligibility	18
Platelet count > 100,000/mm³	Eligibility	19
platelet count	CMO:0000029	0-14
Creatinine clearance > 40 mL/min	Eligibility	20
creatinine clearance	CMO:0000765	0-20
Normal electrolytes (i.e., Na, K, and Ca normal; minor deviations are allowed if they do not impact on patient safety in the clinical judgment of the treating physician)	Eligibility	21
patient	HADO:0000008,OAE:0001817	103-110
Bilirubin  1.5 times upper limit of normal (ULN)	Eligibility	22
ALT and AST  2.5 times ULN ( 5 times ULN in the presence of documented liver metastases)	Eligibility	23
liver	UBERON:0002107	71-76
Alkaline phosphatase  2.5 times ULN ( 5 times ULN in the presence of liver or bone metastases)	Eligibility	24
phosphatase	GO:0016791,BAO:0000295	9-20
liver	UBERON:0002107	69-74
Not pregnant or nursing	Eligibility	25
Fertile patients must use effective barrier contraception	Eligibility	26
No uncontrolled intercurrent illness	Eligibility	27
No active infection requiring systemic therapy	Eligibility	28
active	PATO:0002354	3-9
Able to swallow oral medications and with no medical problems or prior surgeries that may interfere with the absorption of oral medications including the following:	Eligibility	29
Uncontrolled nausea, vomiting, or diarrhea	Eligibility	30
nausea	HP:0002018	13-19
vomiting	HP:0002013	21-29
diarrhea	HP:0002014,DOID:13250	34-42
Lack of the physical integrity of the upper gastrointestinal tract	Eligibility	31
Malabsorption syndrome	Eligibility	32
malabsorption	HP:0002024	0-13
syndrome	DOID:225	14-22
No known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib hydrochloride	Eligibility	33
hypersensitivity	GO:0002524,DOID:1205	9-25
bendamustine	CHEBI:135515	29-41
hydrochloride	CHEBI:36807	42-55
hydrochloride	CHEBI:36807	80-93
mannitol	CHEBI:16899	57-65
erlotinib hydrochloride	CHEBI:53509	70-93
No prior malignancy in the past 5 years except for adequately treated basal cell or squamous cell skin carcinoma, or adequately treated stage I-II cancer for which the patient is in complete remission	Eligibility	34
skin carcinoma	DOID:3451	98-112
cancer	DOID:162	147-153
patient	HADO:0000008,OAE:0001817	168-175
PRIOR CONCURRENT THERAPY:	Eligibility	35
See Disease Characteristics	Eligibility	36
disease	DOID:4,OGMS:0000031	4-11
Prior adjuvant or neoadjuvant chemotherapy and 1 prior chemotherapy regimen in the metastatic setting allowed provided recovered from all acute toxicities	Eligibility	37
adjuvant	CHEBI:60809	6-14
adjuvant	CHEBI:60809	21-29
acute	HP:0011009,PATO:0000389	138-143
No prior bendamustine hydrochloride or EGFR-directed therapy	Eligibility	38
bendamustine	CHEBI:135515	9-21
hydrochloride	CHEBI:36807	22-35
No other concurrent antineoplastic treatments, including radiotherapy, chemotherapy, biological therapy, hormonal therapy, immunotherapy, gene therapy, and surgery	Eligibility	39
radiotherapy	OAE:0000235	57-69
gene	BAO:0000582	138-142
surgery	OAE:0000067	156-163
Intravenous bisphosphonates allowed	Eligibility	40
No concurrent antiretroviral therapy for HIV-positive patients	Eligibility	41
No other concurrent investigational agents	Eligibility	42
Outcome Measurement:	Results	0
Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)	Results	1
bendamustine	CHEBI:135515	26-38
hydrochloride	CHEBI:36807	39-52
28 day cycle included intravenous bendamustine on days 1 and 2.	Results	2
day	UO:0000033	3-6
day	UO:0000033	50-53
bendamustine	CHEBI:135515	34-46
Time frame: Up to two years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Bendamustine and Erlotinib	Results	5
bendamustine	CHEBI:135515	17-29
erlotinib	CHEBI:114785	34-43
Arm/Group Description: Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.	Results	6
bendamustine	CHEBI:135515	87-99
erlotinib	CHEBI:114785	133-142
day	UO:0000033	103-106
day	UO:0000033	146-149
day	UO:0000033	169-172
Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.	Results	7
bendamustine	CHEBI:135515	65-77
erlotinib	CHEBI:114785	111-120
day	UO:0000033	81-84
day	UO:0000033	124-127
day	UO:0000033	147-150
Overall Number of Participants Analyzed: 11	Results	8
Measure Type: Number	Results	9
Unit of Measure: mg/m^2  120	Results	10
Adverse Events 1:	Adverse Events	0
Total: 3/11 (27.27%)	Adverse Events	1
Infection 3/11 (27.27%)	Adverse Events	2
